Quick Note From the Editor - Taking a Closer Look at GTBIF.

Green Thumb Industries marked a 0.9% change today, compared to -2.1% for the S&P 500. Is it a good value at today's price of $13.26? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

  • Green Thumb Industries Inc. engages in manufacture, distribution, and sale of various cannabis products for medical and adult-use in the United States.

  • GREEN THUMB INDUSTRIES IN belongs to the Healthcare sector, which has an average price to earnings (P/E) ratio of 13.21 and an average price to book (P/B) of 4.07

  • The company's P/B ratio is 1.9

  • GREEN THUMB INDUSTRIES IN has a trailing 12 month Price to Earnings (P/E) ratio of 25.5 based on its trailing 12 month price to earnings (Eps) of $0.52 per share

  • Its forward P/E ratio is 35.8 is, based on its 12 month price to earnings (Eps) is $0.52

  • Over the last four years, GREEN THUMB INDUSTRIES IN has averaged free cash flows of $-42,841,962.50, which on average grew -85.6%

  • GTBIF's gross profit margins have averaged 51.1 % over the last four years and during this time they had a growth rate of 6.8 % and a coefficient of variability of 9.1 %.

  • GREEN THUMB INDUSTRIES IN has moved -48.0% over the last year compared to -14.7% for the S&P 500 -- a difference of -33.2%

  • GTBIF has an average analyst rating of buy and is -49.25% away from its mean target price of $26.13 per share

At Market Interference, our goal is to help educate investors about headline-making stocks. We believe informed investment decisions are good investment decisions. Subscribe to our free newsletter to stay on top of each day's market movements!

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS